ADC Choices Require Discretion in HER2-Negative MBC
January 4th 2024As clinicians navigate the array of available antibody-drug conjugates for HER2-negative metastatic breast cancer, Joshua Z. Drago, MD, MS, emphasizes the importance of considering various factors in therapy selection and sequencing.
Zanubrutinib Preferred Over Bendamustine/Rituximas Across CLL/SLL Subgroups
December 15th 2023Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.
Pirtobrutinib Shows Activity in Relapsed/Refractory MCL After Covalent BTK Inhibitor Therapy
December 12th 2023Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.
Longer PFS with Dato-Dxd in HR+/HER2- Inoperable or Metastatic Breast Cancer
December 7th 2023Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
Following Progression on ICIs Lifileucel Shows Anti-tumor Response in Advanced Mucosal Melanoma
October 21st 2023Results of from a subgroup of patients in the phase 2 C-144-01 study with advanced mucosal melanoma showed a clinically meaningful response to lifileucel after progression on immune checkpoint inhibitors.
Immunotherapy, Targeted Therapy Enter Localized Setting in Non–Small Cell Lung Cancer
December 29th 2022According to Benjamin P. Levy, MD, clinicians can use the information currently available to best decide the treatment sequence of immunotherapy vs targeted agents in locally advanced non–small cell lung cancer.